A Study of BBI608 in Adult Patients With Advanced, Refractory Hematologic Malignancies
Public ClinicalTrials.gov record NCT02352558. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase Ib Clinical Study of BBI608 for Adult Patients With Advanced, Refractory Hematologic Malignancies
Study identification
- NCT ID
- NCT02352558
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 1
- Lead sponsor
- Sumitomo Pharma America, Inc.
- Industry
- Enrollment
- 15 participants
Conditions and interventions
Conditions
Interventions
- BBI608 Drug
- Bortezomib Drug
- Dexamethasone Drug
- Ibrutinib Drug
- Imatinib Drug
Drug
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Apr 30, 2015
- Primary completion
- Dec 13, 2018
- Completion
- May 15, 2019
- Last update posted
- Nov 13, 2023
2015 – 2019
United States locations
- U.S. sites
- 8
- U.S. states
- 6
- U.S. cities
- 7
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Rocky Mountain Cancer Centers | Denver | Colorado | 80218 | — |
| Indiana University | Indianapolis | Indiana | 46202 | — |
| West Clinic | Germantown | Tennessee | 38138 | — |
| Cancer Care Centers of South Texas | San Antonio | Texas | 78217 | — |
| Cancer Care Centers of South Texas - HOAST | San Antonio | Texas | 78229 | — |
| Virginia Cancer Specialists, P.C. | Fairfax | Virginia | 22031 | — |
| Virginia Oncology Associates | Norfolk | Virginia | 23502 | — |
| Northwest Cancer Specialists, PC | Vancouver | Washington | 98684 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT02352558, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Nov 13, 2023 · Synced May 17, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT02352558 live on ClinicalTrials.gov.